Background: Leptin, a product of the ob gene controlling food intake, has recently been detected in the stomach and shown to be released by cholecystokinin (CCK) and to induce gastroprotection against various noxious agents, but it is not known whether centrally applied leptin influences gastric secretion and mucosal integrity. Aims: In this study we compared the effects of leptin and CCK-8 applied intracerebroventricularly (i.c.v.) on gastric secretion and gastric mucosal lesions induced by topical application of 75% ethanol. Methods: Several major series of Wistar rats were used in this study. The effects of leptin or CCK applied i.c.v. on gastric secretion were examined using conscious rats with gastric fistulas. For the studies on gastroprotection the following series of rats were used to determine the effects of: (A) leptin and CCK applied centrally on this protection and the blockade of CCKA with loxiglumide (30 mg/kg i.p.) and CCKB receptors with RPR 102681 (30 mg/kg i.p.); (B) cutting of vagal nerves; (C) inactivation of sensory nerves by capsaicin (125 mg/kg s.c.); (D) inhibition of calcitonin gene-related peptide (CGRP) receptors with CGRP8–37 (100 μg/kg i.p.), and (E) suppression of nitric oxide synthase (NOS) with NG-nitro-L-arginine methyl ester (L-NAME) (5 mg/kg i.v.) on ethanol-induced gastric lesions in rats with or without the i.c.v. pretreatment with leptin or CCK-8. Rats were anesthetized 1 h after ethanol administration to measure the gastric blood flow (GBF) and then to determine the area of gastric lesions by planimetry. Blood was withdrawn for the measurement of plasma leptin and gastrin levels by radioimmunoassay and gastric biopsy samples were collected for the determination of cNOS and iNOS mRNA by RT-PCR. Results: Leptin and CCK-8 (0.01–5 μg/kg i.c.v.) dose dependently attenuated gastric lesions induced by 75% ethanol; the doses reducing these lesions by 50% (ED50) were 0.8 and 1.2 μg/kg, respectively. The protective effects of leptin and CCK-8 applied i.c.v. were accompanied by a significant rise in plasma leptin level and an increase in GBF. Blockade of CCKA receptors with loxiglumide abolished the protective and hyperemic effects of CCK but not those of leptin, while RPR 10268, a specific antagonist of CCKB receptors, counteracted leptin-induced protection and the rise in the GBF but failed to influence those afforded by CCK-8. For comparison, pretreatment with peripheral CCK-8 or leptin (10 μg/kg i.p.) causing a similar rise in the plasma leptin level also significantly reduced gastric lesions induced by 75% ethanol. The protective and hyperemic effects of centrally administered leptin were abolished by vagotomy, producing a fall in plasma leptin levels, and significantly attenuated by sensory denervation with capsaicin, by pretreatment with the CGRP antagonist, CGRP8–37, or with L-NAME. A strong signal for iNOS mRNA was recorded in the gastric mucosa of leptin- and CCK-8-treated animals, whereas cNOS mRNA was unaffected. Conclusions: (1) Central leptin exerts a potent gastroprotective action at a dose that has no influence on gastric secretion; (2) this protection depends upon CCKB receptors, vagal activity and sensory nerves, and involves hyperemia probably mediated by NO, and (3) leptin mimics the gastroprotective effect of CCK and may be implicated in the protective and hyperemic actions of this peptide on the rat stomach.

Journal Section:
Original Paper: Stomach
Keywords:
Leptin, Cholecystokinin, Gastroprotection, Nitric oxide, Sensory nerves, Vagal nerves, Gastric blood flow, Gastric secretion
1.
Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998;395:763–770.
[PubMed]
https://doi.org/10.1038/27376
2.
Wang YH, Tache Y, Sheibel AB, Go VLW, Wei JY: Two types of leptin-responsive gastric vagal afferent terminals: An in vitro single-unit study in rats. Am J Physiol 1997;273:833–837.
3.
Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP: Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 1998;43:783–790.
[PubMed]
4.
Houseknecht KL, Baile CA, Matteri RL, Superlock ME: The biology of leptin: A review. J Anim Sci 1998;76:1405–1420.
[PubMed]
5.
Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Millo MG, Le Marchand-Brustel Y, Lewin MJM: The stomach is a source of leptin. Nature 1998;394:790–793.
[PubMed]
https://doi.org/10.1038/29547
6.
Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Duda A, Pierzchalski P, Bielanski W, Hahn EG: Leptin in gastroprotection induced by cholecystokinin or by a meal. Role of vagal nerves and nitric oxide. Eur J Pharmacol 1999;374:263–276.
[PubMed]
https://doi.org/10.1016/S0014-2999(99)00314-3
7.
Hakansson ML, Brown H, Ghilardi N, Skoda RC, Meister B: Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J Neurosci 1998;18:559–572.
[PubMed]
8.
Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y: Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci USA 1997;94:10455–10460.
[PubMed]
https://doi.org/10.1073/pnas.94.19.10455
9.
Matson CA, Wiater MF, Kuijper JL, Weigle DS: Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 1997;18:1275–1278.
[PubMed]
10.
Friedman JM: Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998;56:38–46.
11.
Campfield LA, Smith FJ, Guisez Y: Recombinant mouse OB. protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546–549.
[PubMed]
12.
Halaas JL, Boozer C, Blair-West J: Physiological response to long-term chronic peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997;16:8878–8883.
https://doi.org/10.1073/pnas.94.16.8878
13.
Smith PM, Mollaret V, Ferguson AV: Leptin acts in the rat hypothalamic paraventricular nucleus to induce gastric mucosal damage. Am J Physiol 1998;275:R2081–R2084.
[PubMed]
14.
Miller L: Gastrointestinal hormones and receptors; in Yamada T (ed): Textbook of Gastroenterology, ed 2. Philadelphia, Lippincott, 1999, pp 35–66.
15.
Stroff T, Lambrecht N, Peskar BM: Nitric oxide as mediator of the gastroprotection by cholecystokinin-8 and pentagastrin. Eur J Pharmacol 1994;260:R1–R2.
[PubMed]
https://doi.org/10.1016/0014-2999(94)90019-1
16.
Konturek SJ, Brzozowski T, Pytko-Polonczyk J, Drozdowicz D: Exogenous and endogenous cholecystokinin protects gastric mucosa against the damage caused by ethanol in rats. Eur J Pharmacol 1995;273:57–62.
[PubMed]
17.
Konturek SJ, Brzozowski T, Pytko-Polonczyk J, Drozdowicz D: Comparison of cholecystokinin, pentagastrin and duodenal oleate in gastroprotection in rats. Scand J Gastroenterol 1995;30:620–630.
[PubMed]
18.
Mercer DW, Klemm K, Cross IM, Smith GS, Cashman M, Miller TA: Cholecystokinin induced protection against gastric injury is independent of endogenous somatostatin. Am J Physiol 1996;27:692–700.
19.
Brzozowski T, Konturek PCh, Konturek SJ, Kwiecieñ S, Pajdo R, Brzozowska I, Hahn EG: Involvement of endogenous cholecystokinin and somatostatin in gastroprotection induced by intraduodenal fat. J Clin Gastroenterol 1998;27(suppl 1):125–137.
20.
Lloyd KC, Raybould HE, Walsh JH: Cholecystokinin inhibits gastric acid secretion through type A cholecystokinin receptors and somatostatin in rats. Am J Physiol 1992;263:287–292.
21.
Corwin RL, Smith GP: Different effects of CCKA antagonists on gastric-acid response to CCK and pentagastrin. Peptides 1993;14:253–257.
[PubMed]
https://doi.org/10.1016/0196-9781(93)90038-I
22.
Lloyd KCK, Maxwell V, Kovacs TO, Miller J, Walsh IH: Cholecystokinin receptor antagonist MK329 blocks intestinal fat induced inhibition of meal stimulated gastric acid secretion. Gastroenterology 1992;102:131–138.
[PubMed]
23.
Evangelista S, Maggi CA: Protection induced by cholecystokinin-8 (CCK-8) in ethanol-induced gastric lesions is mediated via vagal capsaicin-sensitive fibers and CCK receptors. Br J Pharmacol 1991;102:119–122.
[PubMed]
24.
Konturek SJ, Bilski J, Cieszkowski M: Role of cholecystokinin in the intestinal fat- and acid-induced inhibition of gastric secretion. Regul Pept 1992;42:97–109.
[PubMed]
https://doi.org/10.1016/0167-0115(92)90027-R
25.
Heinemann A, Jocic M, Peskar BM, Holzer P: CCK-evoked hyperemia in rat gastric mucosa involves neural mechanisms and nitric oxide. Am J Physiol 1996;270:253–258.
26.
Brzozowski T, Konturek SJ, Sliwowski Z, Pytko-Polonczyk J, Szlachcic A, Drozdowicz D: Role of capsaicin-sensitive sensory nerves in gastroprotection against acid-independent and acid-dependent ulcerogens. Digestion 1996;57:424–432.
[PubMed]
27.
Herman ZS: The effects of noradrenaline on rat behavior. Psychopharmacology 1970;16:369–374.
[PubMed]
28.
Brzozowski T, Drozdowicz D, Majka J, Konturek SJ: Studies on gastroprotection induced by capsaicin and papaverine. J Physiol Pharmacol 1992;43:309–322.
[PubMed]
29.
Brzozowski T, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, Stachura J: Role of β-adrenoceptors in gastric mucosal integrity and gastroprotection induced by epidermal growth factor. Digestion 1997;58:319–331.
[PubMed]
30.
Konturek PCh, Brzozowski T, Konturek SJ, Elia G, Wright N, Sliwowski Z, Thim L, Hahn EG: Role of spasmolytic polypeptide in healing of stress-induced gastric lesions in rats. Regul Pept 1997;68:71–79.
[PubMed]
31.
Bohme GA, Bertrand P, Piot O, Boudeau P, Jantaud B, Pauchet C, Guyon C, Manfre F, Imperato A, Dubroucq MC: Pharmacological properties of RPR 102681, a novel CCKB antagonist. Soc Neurosci 1997;23:A2409.
32.
Lloyd KCK, Holzer HH, Zittel TT, Raybould HE: Duodenal lipid inhibits gastric acid secretion by vagal, capsaicin-sensitive afferent pathways in rats. Am J Physiol 1993;264:G659–G663.
[PubMed]
33.
Kato K, Yang H, Tache Y: Role of prostaglandins and calcitonin gene-related peptide in central vagal cholinergic-dependent protection against gastric injury in urethane-anesthetized rats. Digestion 1996;57:322–327.
[PubMed]
34.
Whittle BJR, Lopez-Belmonte J, Moncada S: Regulation of gastric mucosal integrity by endogenous nitric oxide: Interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990;99:607–611.
[PubMed]
35.
Brzozowski T, Konturek SJ, Sliwowski Z, Drozdowicz D, Zaczek M, Kedra D: Role of L-arginine, a substrate for nitric oxide-synthase, in gastroprotection and ulcer healing. J Gastroenterol 1997;32:442–452.
[PubMed]
36.
Green L, Tannenbaum SR, Goldman P: Nitrate synthesis in the germ-free and conventional rat. Science 1981;212:56–58.
[PubMed]
37.
Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109–142.
[PubMed]
38.
Nudel U, Zakut R, Shani M, Neuman S, Levy Z, Yaffe D: The nucleotide sequence of the rat cytoplasmic beta-actin gene. Nucleic Acids Res 1983;11:1759–1771.
[PubMed]
39.
Griffiths MJD, Lin S, Curzen NP, Messent M, Evans IW: In vivo treatment with endotoxin induces nitric oxide synthase in rat main pulmonary artery. Am J Physiol 1995;268:509–518.
40.
Tanoue K, Ohta M, Tarnawski AS, Wahlstrom K, Sugimachi K, Sarfeh IJ: Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology 1996;110:549–557.
[PubMed]
41.
Robert A: Cytoprotection by prostaglandins. Gastroenterology 1979;77:761–767.
[PubMed]
42.
Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM: Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17:305–311.
[PubMed]
43.
Bastaki SM, Waton G, Garner A: Effects of anaesthetic agents on basal and histamine-stimulated acid secretion in the fistula rat. Eur J Gastroenterol Hepatol 1995;7:1199–1202.
[PubMed]
44.
Crawley JN, Fiske SM, Durieux C, Derrien M, Roques P: Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. J Pharmacol Exp Ther 1991;257:1076–1083.
[PubMed]
45.
Attoub S, Levasseur S, Buyse M, Goiot H, Laigneau JP, Moizo L, Hervatin F, Marchand Brustel Y, Lewin JM, Bado A: Physiological role of cholecystokinin B/gastrin receptor in leptin secretion. Endocrinology 1999;140:4406–4410.
[PubMed]
46.
Passaro E, Debas M, Oldendorf W, Yamada T: Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res 1982;241:335–340.
[PubMed]
47.
Schwartz GJ, Berkow G, McHugh PR, Moran TH: Gastric branch vagotomy blocks nutrient and cholecystokinin-induced suppression of gastric emptying. Am J Physiol 1993;264:630–637.
48.
Owyang C: Physiological mechanism of cholecystokinin action on pancreatic secretion. Am J Physiol 1996;27:61–67.
49.
Konturek SJ: Physiology of pancreatic secretion. J Physiol Pharmacol 1998;49:5–23.
50.
Hierlihy LE, Wallace JL, Ferguson AV: Autonomic pathways in development of neural stimulation-induced gastric mucosal damage. Am J Physiol 1994;266:G179–G185.
[PubMed]
51.
Hierlihy LE, Wallace JL, Ferguson AV: Vagal stimulation-induced gastric damage in rats. Am J Physiol 1991;261:G104–G110.
[PubMed]
52.
Hierlihy LE, Wallace JL, Ferguson AV: Neurally mediated gastric mucosal damage in hypophysectomized rats. Can J Physiol 1992;70:1109–1116.
53.
Stroff T, Plate S, Respondek M, Muller KM, Peskar BM: Protection by gastrin in the rat stomach involves afferent neurons, calcitonin gene-related peptide and nitric oxide. Gastroenterology 1995;109:89–97.
[PubMed]
54.
Konturek PCh, Konturek SJ, Brzozowski T, Hahn EG: Gastroprotection and control of food intake by leptin. Comparison with cholecystokinin and prostaglandins. J Physiol Pharmacol 1998;50:39–48.
55.
Feinle C, D’Amato M, Read NW: Cholecystokinin A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gastroenterology 1996; 110:1379–1385.
[PubMed]
56.
Holzer P, Livingston EH, Saria A, Guth PH: Sensory nerves mediate protective vasodilatation in the rat gastric mucosa. Am J Physiol 1991;260:G363–G370.
[PubMed]
© 2000 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2000
You do not currently have access to this content.